Viewing StudyNCT01283516



Ignite Creation Date: 2024-05-05 @ 11:13 PM
Last Modification Date: 2024-10-26 @ 10:30 AM
Study NCT ID: NCT01283516
Status: COMPLETED
Last Update Posted: 2019-03-15
First Post: 2011-01-24

Brief Title: A Dose EscalationExpansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
Sponsor: Novartis Pharmaceuticals
Organization: Novartis

Conditions & Keywords Data

Conditions:
Name
Tumors Characterized by Genetic Abnormalities of ALK
Keywords:
Name View
genetic abnormalities View
ALK inhibitor View
NSCLC View
LDK378 View
ceritinib View